Impact of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial DNA and RNA in Human Skeletal Muscle Cells
Saitoh et al.
Antimicrob. Agents Chemother. 2008;52:2825-2830.
ABSTRACT
| FULL TEXT
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel et al.
NEJM 2008;359:339-354.
ABSTRACT
| FULL TEXT
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper et al.
NEJM 2008;359:355-365.
ABSTRACT
| FULL TEXT
HIV Integrase Inhibitors -- Out of the Pipeline and into the Clinic
Havlir
NEJM 2008;359:416-418.
FULL TEXT
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
Duvivier et al.
J Antimicrob Chemother 2008;0:dkn278v1-12.
ABSTRACT
| FULL TEXT
Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population
Bhaskaran et al.
JAMA 2008;300:51-59.
ABSTRACT
| FULL TEXT
Evaluation of networks of randomized trials
Salanti et al.
Stat Methods Med Res 2008;17:279-301.
ABSTRACT
Co-occurrence of Treatment Nonadherence and Continued HIV Transmission Risk Behaviors: Implications for Positive Prevention Interventions
Kalichman
Psychosom. Med. 2008;70:593-597.
ABSTRACT
| FULL TEXT
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Riddler et al.
NEJM 2008;358:2095-2106.
ABSTRACT
| FULL TEXT
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells
Coffinier et al.
J. Biol. Chem. 2008;283:9797-9804.
ABSTRACT
| FULL TEXT
Stavudine plasma concentrations and lipoatrophy
ter Hofstede et al.
J Antimicrob Chemother 2008;61:933-938.
ABSTRACT
| FULL TEXT
Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors
Hachiya et al.
J. Virol. 2008;82:3261-3270.
ABSTRACT
| FULL TEXT
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle
Proc. Natl. Acad. Sci. USA 2008;105:4832-4837.
Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
Burgoyne and Tan
J Antimicrob Chemother 2008;61:469-473.
ABSTRACT
| FULL TEXT
Efavirenz Accelerates HIV-1 Reverse Transcriptase Ribonuclease H Cleavage, Leading to Diminished Zidovudine Excision
Radzio and Sluis-Cremer
Mol. Pharmacol. 2008;73:601-606.
ABSTRACT
| FULL TEXT
Once-daily dosing of nevirapine in HAART
Clotet
J Antimicrob Chemother 2008;61:13-16.
ABSTRACT
| FULL TEXT
Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3
Sirera et al.
J Antimicrob Chemother 2008;61:191-194.
ABSTRACT
| FULL TEXT
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
Llibre et al.
J Antimicrob Chemother 2008;61:206-209.
ABSTRACT
| FULL TEXT
HIV/AIDS: An update
HARRIS and BOLUS
radtech 2008;79:243-252.
ABSTRACT
| FULL TEXT
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection
Mellgren et al.
Neurology 2007;69:1536-1541.
ABSTRACT
| FULL TEXT
Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment: A Comparison of Different Regimen Types
von Wyl et al.
Arch Intern Med 2007;167:1782-1790.
ABSTRACT
| FULL TEXT
Predictive Genotypic Algorithm for Virologic Response to Lopinavir-Ritonavir in Protease Inhibitor-Experienced Patients
King et al.
Antimicrob. Agents Chemother. 2007;51:3067-3074.
ABSTRACT
| FULL TEXT
Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya
Wools-Kaloustian et al.
Nephrol Dial Transplant 2007;22:2208-2212.
ABSTRACT
| FULL TEXT
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice
Molto et al.
J Antimicrob Chemother 2007;60:436-439.
ABSTRACT
| FULL TEXT
Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue
Chinnadurai et al.
J. Virol. 2007;81:6563-6572.
ABSTRACT
| FULL TEXT
Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients
Parisi et al.
J. Clin. Microbiol. 2007;45:1783-1788.
ABSTRACT
| FULL TEXT
Prognostic Significance of Immune Subset Measurement in Individuals With AIDS-Associated Kaposi's Sarcoma
Stebbing et al.
JCO 2007;25:2230-2235.
ABSTRACT
| FULL TEXT
Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes
Nachega et al.
ANN INTERN MED 2007;146:564-573.
ABSTRACT
| FULL TEXT
Thailand and the Compulsory Licensing of Efavirenz
Steinbrook
NEJM 2007;356:544-546.
FULL TEXT
Psychosocial Aspects of HIV Treatment
Brousseau
JAMA 2007;297:157-158.
FULL TEXT
A Once-Daily Combination Tablet (Atripla) for HIV
Obstet Gynecol 2007;109:195-196.
FULL TEXT
Getting Smarter -- The Toxicity of Undertreated HIV Infection
Currier and Baden
NEJM 2006;355:2359-2361.
FULL TEXT
Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
Kennedy et al.
J. Leukoc. Biol. 2006;80:1175-1182.
ABSTRACT
| FULL TEXT
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
Rodriguez et al.
JAMA 2006;296:1498-1506.
ABSTRACT
| FULL TEXT
Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.
Henry et al.
JAMA 2006;296:1523-1525.
FULL TEXT